T-cell deplete versus T-cell replete haploidentical hematopoietic stem cell transplantation for sickle cell disease: where are we?.
Date
2019-09-12
Authors
Patel, D.A.
Akinsete, A.M.
Connelly, J.A.
Kassim, A.A.
Journal Title
Journal ISSN
Volume Title
Publisher
W B SAUNDERS CO-ELSIEVER INC
Abstract
Introduction: Severe sickle cell disease is associated with progressive end-organ damage and early mortality in adults. While allogeneic hematopoietic cell transplant from a matched related donor is curative, the vast majority of patients do not have a compatible sibling. Accordingly, platforms using haploidentical donors have been developed, which provide near-universal availability. Areas covered: This review focuses on the two commonly used approaches for haploidentical hematopoietic transplants, namely T-cell deplete and T-cell replete, each of which is associated with unique benefits and drawbacks. The purpose of this paper is to facilitate individualized decision-making for patients and providers by reviewing the pros- and cons of these differing approaches. Expert opinion: Individuals with sickle cell disease eligible for a hematopoietic cell transplant can be considered based on recent results. Comparable outcomes are seen with T-cell deplete and T-cell replete approaches. The choice depends largely on institutional preference
Description
Staff publications
Keywords
Haploidentical , Mortality , allogeneic hematopoietic cell transplant , Sickle cell disease , Research Subject Categories::MEDICINE
Citation
Patel, D.A, Akinsete, A.M, Connelly, J.A., Kassim, A.A. T-cell deplete versus T-cell replete haploidentical hematopoietic stem cell transplantation for sickle cell disease: where are we?. Expert Rev Hematol. 2019 Sep;12(9):733-752.